Table 2. Work-flow summary of the top five promising agents in 2018.
Work-flow summary of eribulin, dinutuximab, tyrosine kinase inhibitors, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, and poly-ADP-ribase polymerase (PARP) inhibitors. Ganitumab (currently in a metastatic Ewing sarcoma clinical trial) and mammalian target of rapamycin (mTOR) inhibitors (currently in a trial proposal) are also included using the task force’s work flow for comparison.
| Drug | Basic
Science Evidence |
Preclinical
Evidence |
Clinical
Evidence |
Drug
Availability |
Trial Design
Consideration |
Consensus
Decision |
|---|---|---|---|---|---|---|
|
Ganitumab
(in trial) |
++ | + | ++ | + | ++ | In trial
(AEWS1221) |
|
mTOR inhibitor
(proposed trial) |
++ | + | + | ++ | ++ | Move forward |
|
Anti-GD2
monoclonal |
++ | + | ++ | ++ | Move forward | |
| Eribulin | + | + | + | ++ | ++ | In early trials |
|
Multi-targeted
tyrosine kinase inhibitor |
+ | + | + | ++ | + | In early trials |
| CDK4/6 inhibitor | ++ | ++ | ++ | + | In early trials | |
| PARP inhibitor | ++ | ++ | - | ++ | - | In early trials |
Table 2 - = negative data, + =some evidence, ++ =significant evidence, blank=no data